Fed Agency Grants $14M To Gilgamesh For Cardiac-Safe Ibogaine Analog Targeting Opioid Use Disorder
Clinical-stage neuroscience company Gilgamesh Pharmaceuticals has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, a novel, reportedly cardiac-safe ibogaine analog for the treatment of substance use disorders.
As recently reported in the York Times, the plant-derived psychoactive compound ibogaine holds accumulated data from trials and case reports that point to its robust efficacy as a treatment for substance use disorders.
(See 2024 Stanford study on ibogaine therapy showing promising outcomes for veterans with trauma brain injury.)
Nonetheless, ibogaine’s pharmaceutical development has been hindered by its significant cardiovascular toxicity.
This is where the federal grant comes in by providing funding to support IND-enabling toxicology studies, GMP manufacturing and Phase 1/1b clinical trials in healthy volunteers and Opioid Use Disorder (OUD) patients …